Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.560
-0.020 (-0.78%)
At close: Apr 10, 2026, 4:00 PM EDT
2.550
-0.010 (-0.39%)
After-hours: Apr 10, 2026, 7:53 PM EDT
BDTX Employees
Black Diamond Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 3 or -12.50% compared to the previous year.
Employees
21
Change (1Y)
-3
Growth (1Y)
-12.50%
Revenue / Employee
$3,333,333
Profits / Employee
$1,065,095
Market Cap
146.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -3 | -12.50% |
| Dec 31, 2024 | 24 | -30 | -55.56% |
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Fate Therapeutics | 161 |
| Immunic | 92 |
| Agenus | 81 |
| Tenaya Therapeutics | 70 |
| Spero Therapeutics | 25 |
| TuHURA Biosciences | 22 |
| Galectin Therapeutics | 15 |
BDTX News
- 25 days ago - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 4 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 8 months ago - Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire